Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | Current treatment options for patients with NETs

Jonathan Strosberg, MD, Moffitt Cancer Center, Tampa, FL, highlights the treatment options currently available for various unresectable well-differentiated neuroendocrine tumors (NETs) and discusses novel drugs entering the market; standard first line treatment often involves somatostatin analogues, afinitor is a popular treatment option in liver dominant, pancreatic and other tumors, although the efficacy of afinitor in liver dominant tumors is questionable. 177Lu-DOTATATE is used in midgut and pancreatic tumors, treatment options for the latter also include sunitinib and chemotherapy options. Recently, the multi-tyrosine kinase inhibitor surufatinib has been shown to significantly improve progression-free survival (PFS), in two populations of treatment naïve patients with NETs, with an overall response rate (ORR) of 10-20%, these results suggest that surufatinib could soon be approved to treat NETs. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

Disclosures

Jonathan Strosberg, MD has consulted for Novartis, and received speaker’s bureau fees from Ipsen.